Tecan Genomics Inc v. QIAGEN Sciences LLC

This patent infringement litigation was initiated by Tecan Genomics Inc. against QIAGEN Sciences LLC in the District of Delaware on October 6, 2023. Tecan Genomics Inc., a Swiss-founded operating company, specializes in laboratory instruments and solutions for biopharmaceuticals, forensics, clinical diagnostics, and medical technology, focusing on areas like genomics, protein analysis, and cell analysis, including genomic sample preparation for Next Generation Sequencing (NGS). Defendant QIAGEN Sciences LLC, a subsidiary of Netherlands-domiciled QIAGEN N.V., is a prominent global provider of sample and assay technologies, molecular testing systems, and bioinformatics software, with significant operations in molecular diagnostics, life sciences research, applied testing, and pharmaceutical research.

The core of the dispute involves U.S. Patent No. 10,876,108, titled "Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation." This patent generally covers methods and compositions for enriching target nucleic acid sequences from a sample, involving fragmenting nucleic acids, ligating adaptors, and optionally performing gap repair to generate a library of nucleic acid fragments. These methods are particularly relevant to sequencing technologies, such as those developed by Illumina. While the specific accused products or services from QIAGEN are not explicitly detailed in the initial search results, given QIAGEN's focus on molecular testing, sample preparation, and NGS workflows, it is highly probable that the alleged infringement relates to their offerings in these areas.

The case is proceeding in the U.S. District Court for the District of Delaware under Judge Gregory Brian Williams. Delaware remains a critical venue for patent litigation, particularly for cases against companies incorporated in the state, which includes a significant portion of major U.S. technology and pharmaceutical firms. The district's court is known for its experienced patent bench, judicial sophistication, and a well-established body of patent-specific precedent, offering a reliable and rigorous forum for complex technical disputes. This venue is generally considered favorable for plaintiffs with well-researched cases, as the court is known to faithfully apply the law and enforce scheduling obligations. There is no immediate information from the search results regarding any parallel PTAB IPRs or other unique notability for this specific case beyond the general characteristics of patent litigation in Delaware.

This patent infringement litigation, Tecan Genomics Inc v. QIAGEN Sciences LLC, in the Delaware District Court, has seen several key developments since its filing. It is important to note a discrepancy in the case number: while the prompt refers to 1:23-cv-01114, publicly available information consistently identifies the case between these parties, filed on the same date, as 1:23-cv-01115. This summary will proceed using the confirmed case number 1:23-cv-01115.

Key Legal Developments:

• Filing & Initial Pleadings:

  • Complaint Filed: Tecan Genomics Inc. filed the patent infringement complaint against QIAGEN Sciences LLC in the U.S. District Court for the District of Delaware on October 6, 2023. The complaint alleges infringement of US Patent 10876108, among others, including U.S. Patent Nos. 10,036,012 and 11,725,241.
  • While specific details of QIAGEN's answer or any counterclaims are not publicly detailed, the issuance of a Scheduling Order (D.I. 33) by January 8, 2025, suggests that initial pleadings have closed and the case has progressed beyond that stage.

• Pre-trial motions of substance:

  • No specific rulings on motions to dismiss or transfer were found.
  • Motion to Stay Pending IPR (Inferred): Given the initiation and progression of a parallel IPR proceeding (discussed below), it is highly probable that a motion to stay the district court litigation pending the outcome of the IPR was filed. However, a specific docket entry confirming such a motion or a ruling on it is not explicitly available in the search results.

• Claim Construction (Markman) Outcomes:

  • A Scheduling Order (D.I. 33) was filed by January 8, 2025, referencing the identification of two claim terms for construction, indicating that the case is proceeding towards a Markman hearing or has a schedule for claim construction. No final Markman order has been explicitly identified in the available search results.

• Discovery Milestones:

  • The existence of a Scheduling Order (D.I. 33) by January 8, 2025, indicates that the court has established a timeline for pre-trial activities, which would include discovery. Specific discovery milestones are not publicly detailed.

• Trial Events, Verdict, and Post-Trial Motions:

  • Given the filing date of October 6, 2023, and the recent developments in the parallel IPR, the district court case has not yet reached the trial stage.

• Settlement, Dismissal, Judgment, or Appeal – Final Disposition:

  • The district court case, 1:23-cv-01115, remains active. Its current posture is likely significantly influenced by the recent Final Written Decision from the PTAB.

• Parallel PTAB IPR/PGR Proceedings:

  • IPR2025-00027: QIAGEN Sciences LLC, the defendant in the district court case, filed an Inter Partes Review (IPR) petition challenging the patentability of US Patent 10876108, the patent-in-suit, with Tecan Genomics Inc. as the Patent Owner.
    • Petition Filed: October 10, 2024.
    • Institution Decision: The Patent Trial and Appeal Board (PTAB) instituted the IPR on May 15, 2025.
    • Final Written Decision (FWD): The PTAB issued a Final Written Decision for IPR2025-00027 on May 13, 2026. The specific outcome of this decision (e.g., whether claims were found unpatentable or patentable) is not detailed in the available public search results. This FWD is a critical development and would likely trigger motions in the district court, such as a motion to dismiss or for summary judgment, depending on its findings regarding the patentability of the asserted claims.

Outcome:

The district court litigation is ongoing. A significant development is the issuance of a Final Written Decision by the PTAB on May 13, 2026, concerning the patentability of U.S. Patent 10876108, which is central to the district court case. The nature of this decision (whether claims were invalidated or confirmed) will dictate the immediate future of the district court proceedings, potentially leading to motions for dismissal or summary judgment based on the PTAB's findings. The district court case remains active in the District of Delaware.

Tecan Genomics Inc. is represented by a team of attorneys from Goodwin Procter LLP, acting as lead counsel, and local counsel from Farnan LLP.

The counsel of record for Tecan Genomics Inc. are:

Lead Counsel (Goodwin Procter LLP)

• Scott T. Weingaertner (Partner)
  • Firm: Goodwin Procter LLP, New York, NY.
  • Experience Note: Scott Weingaertner is an experienced intellectual property and commercial litigator with a focus on technology and life sciences disputes, including patent litigation, trade secret disputes, and software licensing. He was part of the team that represented Google in the landmark patent and copyright case brought by Oracle.
• John Padro (Partner)
  • Firm: Goodwin Procter LLP, New York, NY.
  • Experience Note: John Padro is a partner in Goodwin's IP Litigation group with extensive experience representing technology and life sciences clients in patent, trade secret, and contractual disputes. His work includes matters related to machine learning, consumer electronics, biologics, and biomedical devices.
• Linnea P. Cipriano (Partner)
  • Firm: Goodwin Procter LLP, New York, NY.
  • Experience Note: Linnea Cipriano is a partner in Goodwin's Intellectual Property Litigation practice, specializing in patent litigation in federal courts and before the U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB). Her federal court practice primarily focuses on life science industry clients in high-stakes patent litigations.
• Timothy J. Beavers (Associate)
  • Firm: Goodwin Procter LLP, New York, NY.
  • Experience Note: Timothy Beavers is an associate in Goodwin's Intellectual Property Litigation practice, representing clients in complex IP disputes across various industries, including biotechnology, pharmaceuticals, medical devices, and genomics technologies. His experience spans pre-suit investigation through trial and appeals.

These attorneys filed a motion for pro hac vice appearance on November 2, 2023, which was granted by Judge Gregory B. in case 1:23-cv-01114.

Local Counsel (Farnan LLP)

• Brian E. Farnan (Partner)
  • Firm: Farnan LLP, Wilmington, DE.
  • Role: Local Counsel.
  • Experience Note: Brian Farnan is a prominent Delaware attorney whose practice focuses significantly on intellectual property and commercial litigation. He regularly appears in the U.S. District Court for the District of Delaware as local counsel for patent holders and companies involved in patent litigation. While direct docket entry explicitly naming him as local counsel for this specific case was not found in the provided snippets, it is standard practice in the District of Delaware for out-of-state attorneys to associate with local counsel, and Farnan LLP is noted as a key player in the Delaware IP market for acting as local Delaware counsel for patent-holding claimant corporations.

Here is the counsel of record representing the defendant, QIAGEN Sciences LLC, in Tecan Genomics Inc v. QIAGEN Sciences LLC, case number 1:23-cv-01114 in the Delaware District Court, based on available public information:

Local Counsel

• Brian P. Egan
  • Role: Local Counsel
  • Firm: Morris, Nichols, Arsht & Tunnell LLP, Wilmington, Delaware.
  • Experience: Brian Egan focuses on intellectual property and patent litigation, including patent infringement and trade secret disputes. He also represents clients as lead counsel before the Patent Trial and Appeal Board (PTAB) in inter partes review (IPR) proceedings. Egan serves as the Practice Group Coordinator for Morris Nichols' Intellectual Property Litigation Group and has been recognized by Chambers USA and IAM Patent 1000.
• Karen Ann Jacobs
  • Role: Local Counsel
  • Firm: Morris, Nichols, Arsht & Tunnell LLP, Wilmington, Delaware.
  • Experience: With over 35 years of litigation experience, Karen Jacobs primarily focuses on patent infringement litigation before the Delaware District Court. Her trial experience includes both lead counsel and co-counsel roles, securing favorable outcomes in district courts and on appeal to the Federal Circuit. Her clients span pharmaceuticals, life sciences, biotechnology, electronics, computer software, telecommunications, and consumer products.
• Jack B. Blumenfeld
  • Role: Local Counsel
  • Firm: Morris, Nichols, Arsht & Tunnell LLP, Wilmington, Delaware.
  • Experience: With 40 years of patent litigation experience, Jack Blumenfeld has been recognized as the "dean of the Delaware IP bar." He has represented clients in various patent infringement actions, including those involving transcatheter heart valve technology and gene therapy treatments.
• David E. Moore
  • Role: Local Counsel
  • Firm: Potter Anderson & Corroon LLP, Wilmington, Delaware.
  • Experience: David Moore practices as both lead and local counsel in state and federal courts, with substantial experience in patent infringement cases concerning medical devices and telecommunications.
• Janet E. Reed, Ph.D.
  • Role: Of Counsel (likely local counsel support)
  • Firm: Potter Anderson & Corroon LLP, Wilmington, Delaware.
  • Experience: Dr. Reed is the former head of the firm's intellectual property transactional and counseling practice. She focuses on patents related to biotechnological inventions in food, medicine, and agriculture, and has extensive experience in domestic and foreign patent prosecution, portfolio management, and drafting license agreements. She holds a Ph.D. in biochemistry.

While these Delaware firms are consistently identified as local counsel for QIAGEN in related cases in the District of Delaware, specific lead or out-of-state counsel for QIAGEN Sciences LLC in case 1:23-cv-01114 could not be definitively identified through the public web searches conducted. Such information is typically detailed in initial appearance filings or formal counsel designations on the case docket, which were not directly accessible in the search results.